DOP2023000129A - DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS - Google Patents
DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGASInfo
- Publication number
- DOP2023000129A DOP2023000129A DO2023000129A DO2023000129A DOP2023000129A DO P2023000129 A DOP2023000129 A DO P2023000129A DO 2023000129 A DO2023000129 A DO 2023000129A DO 2023000129 A DO2023000129 A DO 2023000129A DO P2023000129 A DOP2023000129 A DO P2023000129A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- cgas
- treatment
- conditions associated
- derivatives useful
- indol derivatives
- Prior art date
Links
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 title 1
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 title 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente revelación se refiere a un compuesto de Formula (I): (I), o a una sal, hidrato, solvato, estereoisómero o tautómero del mismo farmacéuticamente aceptable, donde R1 hasta R8 son como se los define en este documento, así como también a los métodos para hacerlos y usarlos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128949P | 2020-12-22 | 2020-12-22 | |
| PCT/IB2021/062029 WO2022137085A1 (en) | 2020-12-22 | 2021-12-20 | Indole derivatives useful in treating conditions associated with cgas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000129A true DOP2023000129A (es) | 2023-07-16 |
Family
ID=79164465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000129A DOP2023000129A (es) | 2020-12-22 | 2023-06-21 | DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230085472A1 (es) |
| EP (1) | EP4267564A1 (es) |
| JP (1) | JP2024502258A (es) |
| KR (1) | KR20230124665A (es) |
| CN (1) | CN116635382A (es) |
| AR (1) | AR124443A1 (es) |
| AU (1) | AU2021404953A1 (es) |
| CA (1) | CA3202212A1 (es) |
| CL (1) | CL2023001859A1 (es) |
| CO (1) | CO2023007954A2 (es) |
| CR (1) | CR20230282A (es) |
| DO (1) | DOP2023000129A (es) |
| EC (1) | ECSP23045506A (es) |
| IL (1) | IL303913A (es) |
| MX (1) | MX2023007467A (es) |
| PE (1) | PE20240229A1 (es) |
| TW (1) | TW202241873A (es) |
| UY (1) | UY39579A (es) |
| WO (1) | WO2022137085A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230391786A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | cGAS INHIBITORS |
| WO2024083773A1 (en) | 2022-10-18 | 2024-04-25 | Glaxosmithkline Intellectual Property Development Limited | Triazole-substituted imidazo[1,2-a]pyrimidines as cgas inhibitors |
| WO2024137752A1 (en) | 2022-12-21 | 2024-06-27 | Eli Lilly And Company | Azepino[4,5-b]indolone cgas inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| CA2682483A1 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| CA2971755A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| BR112020016008A2 (pt) * | 2018-02-05 | 2020-12-15 | The Rockefeller University | Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica |
-
2021
- 2021-12-20 PE PE2023001937A patent/PE20240229A1/es unknown
- 2021-12-20 CR CR20230282A patent/CR20230282A/es unknown
- 2021-12-20 TW TW110147655A patent/TW202241873A/zh unknown
- 2021-12-20 US US17/645,071 patent/US20230085472A1/en active Pending
- 2021-12-20 JP JP2023537694A patent/JP2024502258A/ja active Pending
- 2021-12-20 WO PCT/IB2021/062029 patent/WO2022137085A1/en active Application Filing
- 2021-12-20 CA CA3202212A patent/CA3202212A1/en active Pending
- 2021-12-20 EP EP21834940.5A patent/EP4267564A1/en active Pending
- 2021-12-20 IL IL303913A patent/IL303913A/en unknown
- 2021-12-20 CN CN202180079723.3A patent/CN116635382A/zh active Pending
- 2021-12-20 MX MX2023007467A patent/MX2023007467A/es unknown
- 2021-12-20 UY UY0001039579A patent/UY39579A/es unknown
- 2021-12-20 AU AU2021404953A patent/AU2021404953A1/en active Pending
- 2021-12-20 AR ARP210103590A patent/AR124443A1/es unknown
- 2021-12-20 KR KR1020237024854A patent/KR20230124665A/ko unknown
-
2023
- 2023-06-20 CO CONC2023/0007954A patent/CO2023007954A2/es unknown
- 2023-06-20 EC ECSENADI202345506A patent/ECSP23045506A/es unknown
- 2023-06-20 CL CL2023001859A patent/CL2023001859A1/es unknown
- 2023-06-21 DO DO2023000129A patent/DOP2023000129A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022137085A1 (en) | 2022-06-30 |
| AU2021404953A1 (en) | 2023-06-22 |
| MX2023007467A (es) | 2023-07-04 |
| TW202241873A (zh) | 2022-11-01 |
| IL303913A (en) | 2023-08-01 |
| JP2024502258A (ja) | 2024-01-18 |
| CR20230282A (es) | 2023-07-12 |
| UY39579A (es) | 2022-07-29 |
| CL2023001859A1 (es) | 2024-02-09 |
| EP4267564A1 (en) | 2023-11-01 |
| ECSP23045506A (es) | 2023-07-31 |
| PE20240229A1 (es) | 2024-02-16 |
| CN116635382A (zh) | 2023-08-22 |
| AR124443A1 (es) | 2023-03-29 |
| US20230085472A1 (en) | 2023-03-16 |
| CO2023007954A2 (es) | 2023-06-30 |
| CA3202212A1 (en) | 2022-06-30 |
| KR20230124665A (ko) | 2023-08-25 |
| AU2021404953A9 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000129A (es) | DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| DOP2020000050A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CL2018003577A1 (es) | Piridina substituida como inhibidor de dnmt1. | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| CO2021017504A2 (es) | Derivados de benzisoxazol sulfonamida | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| UY35641A (es) | PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO) | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| CR20160236A (es) | Derivados de purina 2,6- sustituidos y su uso en el tratamiento de desordenes proliferativos | |
| UY38358A (es) | Inhibidores de sarcómeros cardíacos | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| DOP2023000088A (es) | Derivados de pirazol como inhibidores de la ret-cinasa | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| AR124698A1 (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina |